# Tachycardia â€“ RRT Protocol with Virtua Voorhees Addenda

**Guideline Used:**  
American Heart Association/American College of Cardiology (AHA/ACC) 2020 Advanced Cardiovascular Life Support (ACLS) Guidelines, 2019 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation  
**Official Sources:**  
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000916  
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665

## CARD INTERFACE LAYOUT

### Card 0 â€“ Dynamic Action Card (Node Dependent)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ TACHYCARDIA RRT ACTIVATED                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ â±ï¸ TIME OF ONSET: 30 minutes ago                           â”‚
â”‚ Duration: Continuous | Character: Palpitations with SOB    â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     IMMEDIATE ACTIONS           â”‚                        â”‚
â”‚ â”‚ â˜‘ 12-lead ECG obtained          â”‚ [Completed 15:32]      â”‚
â”‚ â”‚ â˜‘ Continuous telemetry          â”‚ [Monitoring active]    â”‚
â”‚ â”‚ â˜‘ IV access x2                 â”‚ [18G bilateral]        â”‚
â”‚ â”‚ â˜‘ Defibrillator at bedside     â”‚ [Ready, pads on]       â”‚
â”‚ â”‚ â˜ Adenosine ready (if SVT)     â”‚ [6mg drawn up]         â”‚
â”‚ â”‚ â˜ Diltiazem drawn up           â”‚ [Rate control]         â”‚
â”‚ â”‚ â˜ Synchronized cardioversion   â”‚ [Setup if unstable]    â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ Rhythm: Atrial Fibrillation RVR â”‚                        â”‚
â”‚ â”‚ QRS: Narrow (<120ms)            â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ VITALS: HR 148 irregular, BP 108/72, RR 24, SpO2 94% 2L   â”‚
â”‚                                                           â”‚
â”‚ STABILITY ASSESSMENT:                                      â”‚
â”‚ â˜ Chest pain/pressure  â˜ Altered mental status            â”‚
â”‚ â˜ Signs of shock       â˜‘ Mild dyspnea                     â”‚
â”‚                                                           â”‚
â”‚ PATIENT STABLE â†’ Proceed with rate control                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 1 â€“ Static Assessment/Differential

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ TACHYCARDIA DIFFERENTIAL & CAUSES                           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ”´ NARROW COMPLEX (<120ms):                                â”‚
â”‚ â€¢ Regular: Sinus tachycardia, SVT (AVNRT/AVRT), A-flutter  â”‚
â”‚ â€¢ Irregular: Atrial fibrillation, A-flutter variable block â”‚
â”‚                                                           â”‚
â”‚ ğŸ”´ WIDE COMPLEX (â‰¥120ms):                                  â”‚
â”‚ â€¢ Regular: VT (until proven otherwise), SVT with aberrancy â”‚
â”‚ â€¢ Irregular: A-fib with aberrancy, polymorphic VT         â”‚
â”‚                                                           â”‚
â”‚ UNDERLYING CAUSES:                                         â”‚
â”‚ â€¢ Cardiac: Acute MI, heart failure, valvular disease       â”‚
â”‚ â€¢ Metabolic: Hyperthyroidism, electrolyte abnormalities    â”‚
â”‚ â€¢ Drugs/Toxins: Sympathomimetics, anticholinergics        â”‚
â”‚ â€¢ Other: PE, hypoxia, anemia, pain/anxiety, fever/sepsis   â”‚
â”‚                                                           â”‚
â”‚ STABILITY CRITERIA (UNSTABLE if ANY present):              â”‚
â”‚ â€¢ Hypotension (SBP <90 mmHg)                              â”‚
â”‚ â€¢ Acutely altered mental status                            â”‚
â”‚ â€¢ Signs of shock (poor perfusion, cool extremities)        â”‚
â”‚ â€¢ Ischemic chest discomfort                                â”‚
â”‚ â€¢ Acute heart failure                                      â”‚
â”‚                                                           â”‚
â”‚ CRITICAL DECISION POINTS:                                  â”‚
â”‚ Wide vs narrow QRS, regular vs irregular rhythm,          â”‚
â”‚ stable vs unstable hemodynamics, underlying cause          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 2 â€“ Static Physical Exam/Medications

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ PHYSICAL EXAM & MEDICATIONS                                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ HEMODYNAMIC ASSESSMENT:                                    â”‚
â”‚ â€¢ BP: Check for hypotension, pulse pressure               â”‚
â”‚ â€¢ Perfusion: Mental status, skin temp, capillary refill   â”‚
â”‚ â€¢ Volume: JVD, lung sounds, peripheral edema              â”‚
â”‚ â€¢ Cardiac: Regular vs irregular, S3/S4, murmurs           â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š NARROW COMPLEX REGULAR (SVT):                           â”‚
â”‚ â€¢ Vagal maneuvers: Valsalva, carotid massage, ice water   â”‚
â”‚ â€¢ Adenosine: 6mg rapid IV push, then 12mg if no response  â”‚
â”‚ â€¢ Beta-blockers: Metoprolol 2.5-5mg IV q5min (max 15mg)   â”‚
â”‚ â€¢ CCB: Diltiazem 0.25mg/kg IV, then 0.35mg/kg if needed   â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š ATRIAL FIBRILLATION RATE CONTROL:                       â”‚
â”‚ â€¢ Diltiazem preferred if normal EF: Above dosing, then     â”‚
â”‚   5-15mg/hr infusion                                       â”‚
â”‚ â€¢ Metoprolol if CAD: Above dosing, caution in acute HF    â”‚
â”‚ â€¢ Amiodarone if low EF: 150mg IV over 10min, then infusionâ”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š WIDE COMPLEX STABLE VT:                                 â”‚
â”‚ â€¢ Amiodarone: 150mg IV over 10min, may repeat x1          â”‚
â”‚ â€¢ Procainamide: 20-50mg/min IV (max 17mg/kg)              â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š UNSTABLE TACHYCARDIA:                                   â”‚
â”‚ â€¢ Synchronized cardioversion: 100-200J biphasic           â”‚
â”‚ â€¢ Sedation if conscious: Midazolam 2-5mg IV               â”‚
â”‚                                                           â”‚
â”‚ MEDICATION ALERTS: No adenosine in WPW+AF, no AV blockers  â”‚
â”‚ in wide QRS, check electrolytes, consider dig toxicity     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## FLOWCHART (Bottom Panel â€“ Mermaid Algorithm)

```mermaid
graph TD
    A[Tachycardia Recognition 12-lead ECG]
    B{Stable vs Unstable?}
    C[Synchronized Cardioversion]
    D{QRS Width?}
    E[Sedate if conscious 100-200J biphasic]
    F{Regular or Irregular?}
    G[Assume VT Until Proven Otherwise]
    H[Vagal Maneuvers then Adenosine]
    I[AF/Flutter Rate Control]
    J{Stable?}
    K[Amiodarone or Procainamide]
    L{Converts?}
    M[Identify and Treat Underlying Cause]
    N[Beta-blocker or CCB]
    O[Diltiazem/Metoprolol Consider Anticoag]
    P[Continue Monitoring and Treatment]

    A --> B
    B -- Unstable --> C
    B -- Stable --> D
    C --> E
    D -- "Narrow <120ms" --> F
    D -- "Wide â‰¥120ms" --> G
    F -- Regular --> H
    F -- Irregular --> I
    G --> J
    J -- Yes --> K
    J -- No --> C
    H --> L
    L -- Yes --> M
    L -- No --> N
    I --> O
    K --> P
    N --> P
    O --> P
    M --> P
```

## NODE-TO-DYNAMIC CARD PROMPT MAPPING (WITH INTERACTIVES)

| **Step (Node)**                    | **Dynamic Card Prompt/Question**                                                                 | **Interactive Components**                                        |
|-------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| Tachycardia Recognition             | "Tachycardia identified on monitor/ECG. Obtain 12-lead ECG and assess stability?"              | [ECG Acquisition], [HR Monitor], [Rhythm Analysis]                |
| Stability Assessment                | "Evaluate for signs of hemodynamic instability requiring immediate cardioversion?"              | [Stability Checklist], [BP Monitor], [Mental Status Check]        |
| Synchronized Cardioversion          | "Patient unstable with tachycardia. Prepare for immediate synchronized cardioversion?"          | [Cardioversion Setup], [Sedation Protocol], [Energy Selection]    |
| QRS Width Determination             | "Patient stable. Analyze QRS width: narrow (<120ms) or wide (â‰¥120ms)?"                         | [QRS Measurement], [Rhythm Classification], [Lead Analysis]        |
| Regular vs Irregular Assessment     | "Narrow complex tachycardia identified. Is the rhythm regular or irregular?"                   | [Rhythm Regularity], [R-R Interval], [Pattern Recognition]        |
| Wide Complex Evaluation             | "Wide complex tachycardia present. Assume VT until proven otherwise. Assess stability?"        | [VT Criteria], [Stability Reassessment], [Antiarrhythmic Prep]    |
| Vagal Maneuvers and Adenosine       | "Regular narrow complex tachycardia. Attempt vagal maneuvers, then adenosine?"                 | [Vagal Techniques], [Adenosine Administration], [Response Monitor] |
| Atrial Fibrillation Management      | "Irregular narrow complex confirmed as A-fib. Initiate rate control strategy?"                 | [Rate Control Options], [Anticoagulation Risk], [Drug Selection]  |
| SVT Conversion Assessment           | "Adenosine administered for SVT. Did the rhythm convert to sinus?"                             | [Rhythm Conversion], [Post-Conversion Care], [Underlying Cause]    |
| Alternative Rate Control            | "SVT did not convert with adenosine. Consider beta-blocker or calcium channel blocker?"        | [Metoprolol Protocol], [Diltiazem Protocol], [Contraindications]  |
| Stable VT Treatment                 | "Stable wide complex VT confirmed. Administer antiarrhythmic medication?"                      | [Amiodarone Protocol], [Procainamide Option], [Response Monitor]  |
| A-fib Rate Control Implementation   | "A-fib rate control initiated. Monitor response and consider anticoagulation?"                 | [Diltiazem Infusion], [Rate Monitoring], [CHA2DS2-VASc Score]     |
| Underlying Cause Investigation      | "Rhythm converted successfully. Investigate and treat underlying precipitating factors?"        | [Cause Checklist], [Lab Orders], [Further Testing]               |
| Continued Monitoring                | "Tachycardia controlled with appropriate therapy. Continue monitoring and supportive care?"     | [Telemetry Monitoring], [Medication Titration], [Disposition]     |

**Interactive Highlights:**  
- Rate control calculator: weight-based dosing with real-time HR trending
- Rhythm identification tool: step-by-step analysis with differential diagnosis
- Cardioversion energy selector: rhythm-specific energy recommendations
- CHA2DS2-VASc calculator: stroke risk assessment for A-fib anticoagulation
- Adenosine administration tracker: timing and response monitoring

## INTERACTIVE ELEMENTS

### Rate Control Calculator
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      RATE CONTROL CALCULATOR            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Current HR: 148 bpm                     â”‚
â”‚ Target HR: <110 bpm (rest)              â”‚
â”‚ Patient Weight: [80] kg                 â”‚
â”‚                                         â”‚
â”‚ DILTIAZEM PROTOCOL:                     â”‚
â”‚ Initial Bolus: 20mg (0.25mg/kg)        â”‚
â”‚ Time: 15:30 | Response: HRâ†’132 (â†“16)    â”‚
â”‚                                         â”‚
â”‚ Second Bolus: 28mg (0.35mg/kg)         â”‚
â”‚ Available at: 15:45 if HR >110          â”‚
â”‚                                         â”‚
â”‚ Continuous Infusion:                    â”‚
â”‚ Start: 10 mg/hr [â–²â–¼ Adjust]            â”‚
â”‚ Range: 5-15 mg/hr                       â”‚
â”‚                                         â”‚
â”‚ RESPONSE TRACKING:                      â”‚
â”‚ 15:30: 148 bpm (baseline)               â”‚
â”‚ 15:45: 132 bpm (after bolus)           â”‚
â”‚ 16:00: 118 bpm (on infusion)           â”‚
â”‚ 16:15: 108 bpm âœ“ Target achieved        â”‚
â”‚                                         â”‚
â”‚ [CALCULATE DOSE] [TREND HR] [TITRATE]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Rhythm Identification Tool
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      RHYTHM IDENTIFICATION AID          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Step-by-step Analysis:                  â”‚
â”‚                                         â”‚
â”‚ 1. RATE: [148] bpm â— Tachycardia       â”‚
â”‚                                         â”‚
â”‚ 2. QRS WIDTH:                           â”‚
â”‚    â— Narrow (<120ms)                    â”‚
â”‚    â—‹ Wide (â‰¥120ms)                     â”‚
â”‚                                         â”‚
â”‚ 3. RHYTHM REGULARITY:                   â”‚
â”‚    â—‹ Regular                            â”‚
â”‚    â— Irregularly irregular              â”‚
â”‚                                         â”‚
â”‚ 4. P WAVES:                             â”‚
â”‚    â—‹ Present and consistent             â”‚
â”‚    â— Absent/not clearly visible        â”‚
â”‚    â—‹ Flutter waves                      â”‚
â”‚                                         â”‚
â”‚ 5. AV RELATIONSHIP:                     â”‚
â”‚    â—‹ 1:1 conduction                     â”‚
â”‚    â— Variable/no relationship           â”‚
â”‚                                         â”‚
â”‚ DIAGNOSIS: Atrial Fibrillation with RVR â”‚
â”‚                                         â”‚
â”‚ Confidence: 95% | [VIEW ECG STRIPS]     â”‚
â”‚                                         â”‚
â”‚ [CONFIRM DIAGNOSIS] [TREATMENT GUIDE]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Cardioversion Energy Guide
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚    SYNCHRONIZED CARDIOVERSION GUIDE     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Rhythm: Atrial Fibrillation             â”‚
â”‚ Patient Weight: 80 kg                   â”‚
â”‚                                         â”‚
â”‚ ENERGY RECOMMENDATIONS:                 â”‚
â”‚                                         â”‚
â”‚ A-fib/A-flutter:                        â”‚
â”‚ â€¢ Initial: 120-200J biphasic            â”‚
â”‚ â€¢ If unsuccessful: 200J                 â”‚
â”‚ â€¢ Max: 200J biphasic                    â”‚
â”‚                                         â”‚
â”‚ SVT (if refractory to meds):            â”‚
â”‚ â€¢ Initial: 50-100J biphasic             â”‚
â”‚ â€¢ Escalate: 100-200J                    â”‚
â”‚                                         â”‚
â”‚ VT (stable, conscious):                 â”‚
â”‚ â€¢ Initial: 100J biphasic                â”‚
â”‚ â€¢ Escalate: 150J, then 200J             â”‚
â”‚                                         â”‚
â”‚ PRE-CARDIOVERSION CHECKLIST:           â”‚
â”‚ â˜ Synchronized mode ON                  â”‚
â”‚ â˜ Sedation administered                 â”‚
â”‚ â˜ Airway equipment ready                â”‚
â”‚ â˜ Team briefed                          â”‚
â”‚                                         â”‚
â”‚ Recommended: 150J biphasic               â”‚
â”‚                                         â”‚
â”‚ [PREPARE CARDIOVERSION] [SEDATE]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## VIRTUA VOORHEES TACHYCARDIA MANAGEMENT ADDENDA

- **Cardiology Consultation:** 24/7 access via Transfer Center 856-886-5111 for complex arrhythmias and refractory cases
- **Electrophysiology Services:** Advanced EP studies and ablation procedures available with subspecialty referral
- **Anticoagulation Management:** Pharmacy-driven protocols for stroke prevention in atrial fibrillation patients
- **Quality Metrics:** Time to rate control, cardioversion success rates, appropriate anticoagulation initiation

## REFERENCE (GUIDELINE & SOURCE)
American Heart Association/American College of Cardiology. 2020 ACLS Guidelines.  
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000916

**Additional References:**  
2019 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation  
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665

2017 AHA/ACC/HRS Guideline for the Management of Patients with Ventricular Arrhythmias  
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000549

**All steps follow current AHA/ACC ACLS guidelines for tachycardia management with integrated rhythm analysis tools and optimized for rapid identification of unstable patients requiring immediate electrical cardioversion.**
